Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia

Haematologica

Volumn 93, Issue 2, 2008, Pages 178-185

  Lundán, Tuija ^a,b,c   Juvonen, Vesa ^d   Mueller, Martin C ^e   Mustjoki, Satu ^b,e,f   Lakkala, Taina ^g   Kairisto, Veli ^d   Hochhaus, Andreas ^e   Knuutila, Sakari ^a,f   Porkka, Kimmo ^b,f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Biomedicum Helsinki   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF TURKU   (Finland)

Author keywords

BCR ABL; Chronic myeloid leukemia; Minimal residual disease; Real time quantitative PCR; Standardization

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ARTICLE; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METAPHASE; MINIMAL RESIDUAL DISEASE; MITOSIS INDEX; PERIPHERAL CIRCULATION; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION;

BONE MARROW; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES, MONONUCLEAR; MALE; METAPHASE; MITOTIC INDEX; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 40849086557     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11910     Document Type: Article

References (23)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
2. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.
3. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
4. Druker BJ, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-17.
5. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-32.
6. Wang L, Knight K, Lucas C, Clark RE. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006;91:235-9.
7. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17:1707-12.
8. Lundan T, Volin L, Elonen E, Autio K, Knuutila S. Clinical and practical value of metaphase fluorescent in situ hybridization in follow-up after allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica 2004;89:247-9.
9. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925-30.
10. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
11. El-Rifai W, Ruutu T, Elonen E, Volin L, Knuutila S. Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission. Blood 1997;89:3330-4.
12. Hamalainen MM, Eskola JU, Hellman J, Pulkki K. Major interference from leukocytes in reverse transcription-PCR identified as neurotoxin ribonuclease from eosinophils: detection of residual chronic myelogenous leukemia from cell lysates by use of an eosinophil-depleted cell preparation. Clin Chem 1999;45:465-71.
13. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17:2318-57.
14. Branford S, Cross NCP, Hochhaus A, Radich J, Saglio G, Kim DW, et al. First results from a collaborative initiative to develop an International Scale for the measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors. American Society of Hematology ASH. Orlando, Florida, USA. Blood 2006:737.
15. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 348:994-1004.
16. Paschka P, Muller MC, Merx K, Kreil S, Schoch C, Lahaye T, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pre-treated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 2003;17:1687-94.
17. Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003;17:2401-9.
18. Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon a/ara-C. Leukemia 2003;17:2392-400.
19. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001;97: 1560-5.
20. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160-6.
21. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999;107:587-99.
22. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002;16:53-9.
23. Wang YL, Lee JW, Cesarman E, Jin DK, Csernus B. Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts. J Mol Diagn 2006;8:231-9.